MARKET

INCY

INCY

Incyte Corp
NASDAQ
108.39
+5.63
+5.48%
After Hours: 107.91 -0.48 -0.44% 19:26 02/06 EST
OPEN
103.75
PREV CLOSE
102.76
HIGH
108.52
LOW
103.52
VOLUME
2.19M
TURNOVER
--
52 WEEK HIGH
112.29
52 WEEK LOW
53.56
MARKET CAP
21.28B
P/E (TTM)
18.33
1D
5D
1M
3M
1Y
5Y
1D
Incyte Is Maintained at Overweight by Piper Sandler
Dow Jones · 1d ago
Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $110
Benzinga · 1d ago
Incyte price target raised to $110 from $102 at Piper Sandler
TipRanks · 1d ago
INCYTE <INCY.O>: PIPER SANDLER RAISES TARGET PRICE TO $110 FROM $102
Reuters · 1d ago
How Investors Are Reacting To Incyte (INCY) EMA Backing For Zynyz Combo In First-Line Anal Cancer
Simply Wall St · 2d ago
Incyte’s Zynyz Wins CHMP Backing And Opens New EU Opportunity
Simply Wall St · 2d ago
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
Benzinga · 2d ago
Microsoft downgraded, Snap upgraded: Wall Street’s top analyst calls
TipRanks · 2d ago
More
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.